X4 Pharmaceuticals Inc.
07/23/2021 | Press release | Distributed by Public on 07/23/2021 14:05
Material Event (Form 8-K)
|
Other Events
|
On July 20, 2021, X4 Pharmaceuticals, Inc. (the 'Company') notified Abingworth LLP ('Abingworth') that it no longer intends to pursue a co-development arrangement with Abingworth. Pursuant to that certain Option Agreement, dated March 18, 2021 and as amended to date, between the Company and Abingworth Bioventures 8 LP ('Abingworth Bioventures 8'), an affiliate of Abingworth, as a result of the termination of the letter of intent between the Company and Abingworth related to the contemplated co-development arrangement, Abingworth Bioventures 8 has the right until September 2, 2021 to require the Company, subject to applicable law, to repurchase, at the original purchase price of $8.70 per share, $2.0 million of shares of the Company's common stock that Abingworth Bioventures 8 purchased from the Company in a previously announced private placement in March 2021.
| Financial Statements and Exhibits | |
| Exhibit No. | Description |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |